The Dose-Dependent Effect of Chronic Administration of Haloperidol, Risperidone, and Quetiapine on Sexual Behavior in the Male Rat

Journal of Sexual Medicine

Volumn 8, Issue 12, 2011, Pages 3345-3353

  Zhang, Xiang Rong ^a,b,c   Zhang, Zhi Jun ^a,b   Jenkins, Trisha A ^c   Cheng, Wei Rong ^d   Reynolds, Gavin P ^c  

^a SOUTHEAST UNIVERSITY   (China)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Antipsychotics; Male rat; Sexual behavior; Sexual dysfunction

Indexed keywords

HALOPERIDOL; QUETIAPINE; RISPERIDONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; COPULATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; EJACULATION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

EID: 82955226486     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01740.x     Document Type: Article

References (67)

1. Mallis D, Moisidis K, Kirana PS, Papaharitou S, Simos G, Hatzichristou D. Moderate and severe erectile dysfunction equally affects life satisfaction. J Sex Med 2006;3:442-9.
2. Olfson M, Uttaro T, Carson WH, Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005;66:331-8.
3. Finn SE, Bailey JM, Schultz RT, Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 1990;20:843-8.
4. Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, Golks D, Naber D. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004;19:415-22.
5. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8.
6. Rosenberg KP, Bleiberg KL, Koscis J, Gross C. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: Impact on compliance. J Sex Marital Ther 2003;29:289-96.
7. Westheide J, Cohen S, Bender S, Cooper-Mahkorn D, Erfurth A, Gastpar M, Huber TJ, Maier W, Murafi A, Rothermund M, Signerski J, Strater B, Teusch L, Weig W, Welling A, Kuhn KU. Sexual dysfunction in psychiatric inpatients the role of antipsychotic medication. Pharmacopsychiatry 2007;40:140-5.
8. Plevin D, Galletly C, Roughan P. Sexual dysfunction in men treated with depot antipsychotic drugs: A pilot study. Sex Health 2007;4:269-71.
9. Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 2007;68:361-7.
10. Higgins A, Barker P, Begley CM. Neuroleptic medication and sexuality: The forgotten aspect of education and care. J Psychiatr Ment Health Nurs 2005;12:439-46.
11. Macdonald S, Halliday J, MacEWAN T, Sharkey V, Farrington S, Wall S, McCreadie RG. Nithsdale Schizophrenia Surveys 24: Sexual dysfunction. Case-control study. Br J Psychiatry 2003;182:50-6.
12. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003;28:69-82.
13. Kelly DL, Conley RR. Sexuality and schizophrenia: A review. Schizophr Bull 2004;30:767-79.
14. Baggaley M. Sexual dysfunction in schizophrenia: Focus on recent evidence. Hum Psychopharmacol 2008;23:201-9.
15. Bobes J, Garc A, Rejas J, Hern NG, Garcia-Garcia M, Rico-Villademoros F, Porras A. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. J Sex Marital Ther 2003;29:125-47.
16. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A, Shakhnovich T, Akram A, Pecenak J, McBride M, Treuer T. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006;21:251-8.
17. Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry 2001;62:541-4.
18. Mullen B, Brar JS, Vagnucci AH, Ganguli R. Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone. Schizophr Res 2001;48:155-8.
19. Strous RD, Kupchik M, Roitman S, Schwartz S, Gonen N, Mester R, Weizman A, Spivak B. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: A naturalistic prospective 12-week observational study. Hum Psychopharmacol 2006;21:235-43.
20. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999;156:631-3.
21. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137-41.
22. Pfaus JG, Phillips AG. Role of dopamine in anticipatory and consummatory aspects of sexual behavior in the male rat. Behav Neurosci 1991;105:727-43.
23. Pehek EA, Thompson JT, Eaton RC, Bazzett TJ, Hull EM. Apomorphine and haloperidol, but not domperidone, affect penile reflexes in rats. Pharmacol Biochem Behav 1988;31:201-8.
24. Benassi-Benelli A, Ferrari F, Quarantotti BP. Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats. Arch Int Pharmacodyn Ther 1979;242:241-7.
25. Pfaus JG, Phillips AG. Differential effects of dopamine receptor antagonists on the sexual behavior of male rats. Psychopharmacology 1989;98:363-8.
26. Chen KK, Chan JY, Chang LS. Dopaminergic neurotransmission at the paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat. J Urol 1999;162:237-42.
27. Zhang X, Zhang Z, Cheng W, Mou X, Reynolds GP. The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat. J Psychopharmacol 2007;21:428-34.
28. Compton MT, Miller AH. Sexual side effects associated with conventional and atypical antipsychotics. Psychopharmacol Bull 2001;35:89-108.
29. Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, van den Bosch RJ. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004;24:56-61.
30. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-28.
31. Agmo A. Male rat sexual behavior. Brain Res Brain Res Protoc 1997;1:203-9.
32. Clark JT. Sexual function in altered physiological states: Comparison of effects of hypertension, diabetes, hyperprolactinemia, and others to "normal" aging in male rats. Neurosci Biobehav Rev 1995;19:279-302.
33. Melis MR, Argiolas A. Dopamine and sexual behavior. Neurosci Biobehav Rev 1995;19:19-38.
34. Sachs BD. Conceptual and neural mechanisms of masculine copulatory behaviour in the rat. In: McGill TE, Dewsbury DA, Sachs BD (Eds), Sex and behavior: Status and Prospectus, New York; Plenum; 1978;267-95.
35. Pfaus JG, Mendelson SD, Phillips AG. A correlational and factor analysis of anticipatory and consummatory measures of sexual behavior in the male rat. Psychoneuroendocrinology 1990;15:329-40.
36. Ratnasooriya WD, Ratnayake SS, Jayatunga YN. Effects of pyrethroid insecticide ICON (lambda cyhalothrin) on reproductive competence of male rats. Asian J Androl 2002;4:35-41.
37. Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002;56:25-30.
38. Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: Influences on male sexual behavior. Physiol Behav 2004;83:291-7.
39. Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506-33.
40. Dominguez JM, Hull EM. Dopamine, the medial preoptic area, and male sexual behavior. Physiol Behav 2005;86:356-68.
41. Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 2001;25:476-88.
42. Turrone P, Remington G, Kapur S, Nobrega JN. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology 2003;165:166-71.
43. Cheng YF, Paalzow LK, Bondesson U, Ekblom B, Eriksson K, Eriksson SO, Lindberg A, Lindstrom L. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology 1987;91:410-4.
44. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van GP, Lesage AS, De LK, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
45. Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006;31:340-6.
46. Byerly MJ, Nakonezny PA, Bettcher BM, Carmody T, Fisher R, Rush AJ. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006;86:244-50.
47. Rueter LE, Ballard MF, Gallagher KB, Basso AM, Curzon P, Kohlhaas KL. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology 2004;176:312-9.
48. van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, Heykants JJ. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 1994;114:53-62.
49. Aravagiri M, Marder SR. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology 2002;159:424-31.
50. Gorzalka BB, Hanson LA. Sexual behavior and wet dog shakes in the male rat: Regulation by corticosterone. Behav Brain Res 1998;97:143-51.
51. Gorzalka BB, Brotto LA, Hong JJ. Corticosterone regulation of 5-HT2A receptor-mediated behaviors: Attenuation by melatonin. Physiol Behav 1999;67:439-42.
52. Klint T, Larsson K. Clozapine acts as a 5-HT2 antagonist by attenuating DOI-induced inhibition of male rat sexual behaviour. Psychopharmacology 1995;119:291-4.
53. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: Impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381-91.
54. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65:57-61.
55. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170:463-7.
56. Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 2007;33:203-16.
57. Drago F. Prolactin and sexual behavior: A review. Neurosci Biobehav Rev 1984;8:433-9.
58. Rourke C, Starr KR, Reavill C, Fenwick S, Deadman K, Jones DN. Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: A comparison with clinical data. Psychopharmacology 2006;184:107-14.
59. Atmaca M, Kuloglu M, Tezcan E. A new atypical antipsychotic: Quetiapine-induced sexual dysfunctions. Int J Impot Res 2005;17:201-3.
60. Byerly MJ, Lescouflair E, Weber MT, Bugno RM, Fisher R, Carmody T, Varghese F, Rush AJ. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J Sex Marital Ther 2004;30:325-32.
61. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: Preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63(13 suppl):5-11.
62. Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F, Lindstrom L. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: A PET study. Eur Neuropsychopharmacol 2001;11:105-10.
63. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-84.
64. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. J Clin Psychopharmacol 2007;27:639-61.
65. Karl T, Duffy L, O'brien E, Matsumoto I, Dedova I. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behav Brain Res 2006;171:286-94.
66. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
67. Hertel P. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: Mechanism of action. Synapse 2006;60:543-52.